Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Transplant versus no transplant in myelodysplastic syndrome and acute myeloid leukemia with TP53 mutation; a referral center experience.

European journal of haematology - 1 Jul 2024

Poonsombudlert Kittika, Mott Sarah, Miller Benda, Dhakal Prajwal, Snow Anthony, Hornberg Sarah, Yodsuwan Ratdanai, Strouse Christopher, Shaikh Hira, Magalhaes-Silverman Margarida, Sutamtewagul Grerk

Abstract excerpt

A remarkably high rate of post-transplant relapse in patients with TP53-mutated myelodysplastic syndrome/acute myeloid leukemia (MDS/AML) calls to question the utility of allogeneic stem cell transplant (HSCT). We, therefore, performed a retrospective analysis to compare the outcomes between HSCT (N = 38) versus non-HSCT (N = 45) approaches. Patients in the HSCT cohort were younger (median age 63 vs. 72) while...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Graft vs Host Disease
Share to Hematopoietic Stem Cell Transplantation

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Leukemia, Myeloid, Acute

Share to Myelodysplastic Syndromes

Share to Prognosis

Share to Transplantation, Homologous

Share to Treatment Outcome

Share to Tumor Suppressor Protein p53

Source

Identifiers

PMID: 38511425
DOI: 10.1111/ejh.14199

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-07.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Transplant versus no transplant in myelodysplastic syndrome and acute myeloid leukemia with TP53 mutation; a referral center experience.PMID 38511425Read ↗

Utility or futility? A contemporary approach to allogeneic hematopoietic cell transplantation for TP53- mutated MDS/AMLSemantic proximity Read ↗

Remission Status Prior to Allogeneic Stem Cell Transplantation in Acute Myeloid Leukemia/Myelodysplastic Syndrome Patients Harboring Single-Hit or Multi-Hit p53 Mutations Does Not Impact Outcome.Semantic proximity Read ↗

Impact of TP53 alteration on allogeneic hematopoietic cell transplantation outcomes for myelodysplastic syndromes.Semantic proximity Read ↗

Transplant for TP53-mutated MDS and AML: because we can or because we should?Semantic proximity Read ↗

Acute Myeloid Leukemia and Myelodysplastic Syndromes with TP53 Aberrations - A Distinct Stem Cell Disorder.Semantic proximity Read ↗

Allogeneic Hematopoietic Cell Transplantation in Patients With Acute Myeloid Leukemia With Myelodysplasia-Related Genetic Features: Relevance of the Genetic Underlying Category. A Retrospective Analysis on Behalf of the Acute Leukemia Working Party of the EBMT.Semantic proximity Read ↗

TP53-mutant variant allele frequency and cytogenetics determine prognostic groups in MDS/AML for transplantationSemantic proximity Read ↗

Transplant options and outcomes for TP53 myeloid disease.Semantic proximity Read ↗

Clinical outcomes and characteristics of patients with TP53-mutated acute myeloid leukemia or myelodysplastic syndromes: a single center experience.Semantic proximity Read ↗

Comparison of acute myeloid leukemia and myelodysplastic syndromes with TP53 aberrations.Semantic proximity Read ↗

TP53 mutation defines a unique subgroup within complex karyotype de novo and therapy-related MDS/AML.Semantic proximity Read ↗

Nontransplant treatment approaches for myeloid neoplasm with mutated TP53.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.